Market Research Report
OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026
|Published by||GlobalData||Product code||574488|
|Published||Content info||318 Pages
Delivery time: 1-2 business days
|OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026|
|Published: August 1, 2017||Content info: 318 Pages||
Sepsis is a complex disease, which not only involves a wide array of causative agents, but also results in different individual immune responses causing various single or multiple organ dysfunction(s). In late 2016, the sepsis and septic shock market abandoned the concept of a systemic immune response syndrome in the presence of an infection as a potential cause for sepsis; in the new consensus definitions, sepsis is defined as an infection leading to organ dysfunction.
It is estimated that in 2015, the overall sales for sepsis and septic shock to be approximately US$2.8 Billion, comprising annual drug sales of US$2.2 Billion in sepsis and US$0.6 Billion in septic shock across the 7MM. Differences in revenue generated by disease area are due to higher incidence rates for sepsis compared with septic shock. GlobalData expects the sepsis and septic shock market to grow by a strong Compound Annual Growth Rate (CAGR) of 7.9% from 2016-2026, reaching annual sales of US$5.9 Billion by the end of the forecast period.
In order to combat these market realities, we believe developers will have to leverage innovative R&D strategies to establish the strong clinical evidence needed for approval and uptake post-licensure. Some of the key approaches identified by KOLs include adaptive clinical trial design, including interim analyses leveraging multiple clinically relevant biomarkers and companion diagnostics to limit heterogeneity among enrolled patients; targeting highly specific sepsis patient populations based on sepsis-induced conditions; and investigating novel targets with combination therapies that are relevant to sepsis pathophysiology.
The report "OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026", covers overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well as current routine sepsis and septic shock recommendations of all 7MM covered.
This report provides the following in-depth analysis -
Companies mentioned in this report: AM-Pharma, Asahi Kasei Pharma Corp, Bristol-Myers Squibb, CytoSorbents, Faron, Ferring Holding, Pfizer, RevImmune, Shionogi, Spectral Diagnostics.
The report will enable you to -